Latest Cancer News
Yondelis Fights Deadly Soft-Tissue Cancer
By Daniel J. DeNoon
WebMD Health News
Reviewed by Louise Chang, MD
The drug, generically known as trabectedin and formerly called ecteinascidin or ET-743, is branded as Yondelis by maker PharmaMar. It was originally made from a sea squirt -- the translucent, siphon-like organism also known as the mangrove tunicate. Yondelis is now synthetically manufactured.
Myxoid liposarcoma is a killer. It tends to start deep within the body and spreads quickly. Even when the primary tumor is removed, the cancer spreads to other organs in about 40% of patients. Survival from this point is usually about two years.
Yondelis fights this cancer better than any other known treatment, report Federica Grosso, MD, of Italy's National Cancer Institute in Milan, and colleagues. Their report appears in the June 21 issue of The Lancet.
Grosso and colleagues treated 51 myxoid liposarcoma patients with Yondelis. The results, a median 14 months after treatment:
- Two patients have no evidence of disease.
- 24 patients had partial responses to treatment.
- Overall, more than half of patients responded to treatment.
- Median progression-free survival after treatment was 14 months.
Yondelis is not without side effects. But it appears to have side effects that are tolerated well, allowing multiple courses of treatment. The most common side effect noted is elevation of liver enzymes that is reversible. The drug does not cause hair loss or diarrhea.
Advanced clinical trials are under way for myxoid liposarcoma -- and for ovarian cancer. Yondelis is being tested in a major, phase III clinical trial for ovarian cancer. It's no cure, but early results look promising. It already has FDA and European Commission "orphan drug" status, making it available for the treatment of soft-tissue sarcomas and ovarian cancer.
PharmaMar has partnered with Johnson & Johnson to develop Yondelis.
SOURCES: Grosso, F. The Lancet, published online June 21, 2007. PharmaMar web site. Medscape: "Trabectedin Effective in Platinum-Sensitive Ovarian Cancer Patients," Nov. 10, 2006.
© 2007 WebMD, Inc. All rights reserved.